Medical Equipment Stocks on Investors' Radar -- St. Jude Medical, Edwards Lifesciences, Zimmer Biomet, and Stryker

Wednesday, November 9, 2016 Medical Gadgets
Email Print This Page Comment

NEW YORK, November 9, 2016 /PRNewswire/ --

This morning, revisits the Medical Appliances and Equipment

space, which is one of the biggest industries in healthcare, driven by innovation and new technologies. Equities to assess today are: St. Jude Medical Inc. (NYSE: STJ), Edwards Lifesciences Corp. (NYSE: EW), Zimmer Biomet Holdings Inc. (NYSE: ZBH), and
Stryker Corp. (NYSE: SYK). Learn more about these stocks by downloading their comprehensive and free reports at:

St. Jude Medical  

St. Paul, Minnesota headquartered St. Jude Medical Inc.'s stock finished Tuesday's session 0.01% lower at $78.95, with a total trading volume of 1.69 million shares. The Company's shares have advanced 29.57% on an YTD basis. The stock is trading 0.18% and 11.44% above its 50-day and 200-day moving averages, respectively. Additionally, shares of St. Jude Medical, which together with its subsidiaries, develops, manufactures, and distributes cardiovascular medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide, have a Relative Strength Index (RSI) of 52.73.

On November 02nd, 2016, St. Jude Medical presented favorable results from the largest observational study to date of its AMPLATZER™ Amulet™ left atrial appendage (LAA) occluder. The prospective, multicenter, international AMPLATZER Amulet Observational Study of LAA occlusion (closure) enrolled 1,073 patients at 64 centers across 18 countries. Initial results from the study showed a 98.8% implant success rate adding to the clinical evidence that the AMPLATZER Amulet LAA Occluder is a safe alternative for prevention of stroke in patients with non-valvular atrial fibrillation. STJ complete research report is just a click away and free at:

Edwards Lifesciences  

On Tuesday, shares in Irvine, California headquartered Edwards Lifesciences Corp. recorded a trading volume of 1.65 million shares. The stock ended the session 0.05% higher at $91.39. The Company's shares have advanced 15.71% since the start of this year. The stock is trading 10.96% below its 200-day moving average. Moreover, shares of Edwards Lifesciences, which provides products and technologies to treat structural heart disease and critically ill patients worldwide, have an RSI of 26.72.

On November 01st, 2016, Edwards Lifesciences announced new 5-year hemodynamic data from the PARTNER Trial demonstrating excellent durability of the first-generation Edwards SAPIEN transcatheter heart valve. This evaluation of 2,404 patients, encompassing 10,560 echoes and 6,493 patient years of follow-up, is the largest core lab based study of transcatheter heart valves to date. Using three standard echocardiographic parameters, the study assessed hemodynamics and related the findings to clinical events of death and aortic valve re-intervention.

Yesterday, research firm Northland Capital upgraded the Company's stock rating from 'Market Perform' to 'Outperform'. The complimentary report on EW can be downloaded at:

Zimmer Biomet  

Shares in Warsaw, Indiana headquartered Zimmer Biomet Holdings Inc. closed the day 2.51% lower at $101.83. The stock recorded a trading volume of 5.19 million shares, which was higher than its three months average volume of 1.47 million shares. The Company's shares are trading 12.48% below their 200-day moving average. Additionally, shares of Zimmer Biomet, which together with its subsidiaries, provides musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia/Pacific, have an RSI of 21.94.

On October 31st, 2016, Zimmer Biomet reported Q3 2016 net sales of $1.83 billion, an increase of 4.0% compared to Q3 2015. Diluted earnings per share for the reported quarter were $0.78, an increase of 609.1% over Q3 2015, and adjusted diluted earnings per share were $1.79, an increase of 9.1% over Q3 2015.

On November 01st, 2016, research firm Needham upgraded the Company's stock rating from 'Buy' to 'Strong Buy'. The research firm also revised downwards its previous target price from $150 to $148. Sign up for your complimentary research report on ZBH at:


At the close, shares in Kalamazoo, Michigan headquartered Stryker Corp. ended at $120.85, rising 0.98%. The stock recorded a trading volume of 1.53 million shares, which was above its three months average volume of 1.19 million shares. The Company's shares have advanced 2.55% in the last one month, 4.94% over the previous three months, and 31.36% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 5.24% and 9.17%, respectively. Furthermore, shares of Stryker, which together with its subsidiaries, operates as a medical technology company, have an RSI of 68.33.

On October 14th, 2016, research firm SunTrust initiated a 'Buy' rating on the Company's stock.

On October 27th, 2016, Stryker reported that during Q3 2016 consolidated net sales of $2.8 billion increased 17.1% as reported and 16.7% in constant currency. The company's reported net earnings of $355 million increased 17.9% in Q3 2016. Get free access to your research report on SYK at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store